Esperante
Overview
Esperante is a corporate venture capital firm that is part of a family-controlled global life science group, focusing on investments in mid to late-stage clinical therapeutics development companies in North America, Europe, and Israel.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| AMLo Biosciences | Nov 2022 | VC Round | Lead |
| Acousia Therapeutics GmbH | Jan 2024 | VC Round | - |
| Kiyatec | Jan 2020 | VC Round | Co-investor |
| Spiral Therapeutics | Aug 2023 | VC Round | Lead |
| Reconnect Labs | Aug 2025 | Series A | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Esperante based?
Esperante is headquartered in Hoofddorp, Netherlands.
When was Esperante founded?
Esperante was founded in 2004.
How many portfolio companies does Esperante have?
Esperante has 9 portfolio companies in Caplight's dataset.
What are some companies in Esperante's portfolio?
Portfolio companies visible on Caplight include AMLo Biosciences, Acousia Therapeutics GmbH, Kiyatec, Spiral Therapeutics, Reconnect Labs.
What was Esperante's most recent investment shown here?
Esperante's most recent investment in this portfolio sample was in Reconnect Labs in 2025.
What sectors does Esperante focus on?
Esperante focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Esperante focus on?
Esperante typically invests at the Early stage.
What is Esperante's AUM?
Esperante's assets under management are estimated between $50.0M and $100.0M.